Muhammad Shahab, Abdul Wadood* and Guojun Zheng* Pages 2343 - 2348 ( 6 )
Breast cancer is a common malignancy in women and is a diverse disease. In women, 287,850 and in males 2710 cases are reported in 2022 by WHO. Triple-negative breast cancer (TNBC), a subtype of breast cancer that lacks expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), accounted for 10-20% of all new cases discovered in the United States in 2017. Because calcium integrin-binding protein1 lacks a suitable pocket that could be used to create a chemical inhibitor, and because the breast cancer-causing protein is nearly identical to its necessary wild-type counterpart, it was thought to be druggable. The structure and function of the newly discovered calcium integrinbinding protein1 have been improved, paving the way for the designing of several therapeutic candidates. Currently, no FDA-approved drugs are available for CIB1-driven cancer. CIB1 has proven to challenge drug target due to several factors, including the fact that the CIB1 protein is highly resistant to small inhibitors. This study aimed to present various ways for targeting calcium integrin-binding protein1, which is an important target that could be useful to scientists.
CIB1 protein, breast cancer, TNBC, HER2, progesterone receptor, estrogen receptor.